Literature DB >> 22025577

Phenotypic and genotypic characterization of coagulase negative staphylococci (CoNS) other than Staphylococcus epidermidis isolated from ocular infections.

Abhijith R Makki1, Savitri Sharma, Aparna Duggirala, K Prashanth, Prashant Garg, Taraprasad Das.   

Abstract

PURPOSE: The clinical significance of many species belonging to coagulase-negative staphylococci (CoNS) other than Staphylococcus epidermidis has been increasingly recognized. The present study attempted the characterization of non-S. epidermidis CoNS isolates of ocular origin.
METHODS: The isolates were characterized phenotypically by analytical profile index (API) and genotypically by fluorescent amplified fragment length polymorphism (FAFLP). In addition, the presence of genes that are likely to enhance virulence such as biofilm related genes (icaA and icaB) and methicillin resistance (mecA) were detected.
RESULTS: API identified seven different species with an identification score varying from 44% to 99%. S. haemolyticus and S. xylosus species identified by API showed good API scores when compared with all other species identified. FAFLP generated 12 clusters from all the isolates and appeared to be more discriminatory. API identification results corresponded well with the FAFLP results only in six clusters. Nearly 40% of isolates showed the presence of mecA and icaAB genes.
CONCLUSIONS: Identification results of these two methods corresponded only in 48.4% of the isolates suggesting that the battery of tests using API were not sufficient enough to identify all the species of CoNS. Therefore, it is sensible to rely on two or more identification methods particularly when API species identification has a lower score. FAFLP genotyping appears to be a reliable and rapid alternative identification method for CoNS that can be used in conjunction with any other phenotypic method.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025577     DOI: 10.1167/iovs.11-7777

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

Review 1.  Clinical Infections, Antibiotic Resistance, and Pathogenesis of Staphylococcus haemolyticus.

Authors:  Hala O Eltwisy; Howida Omar Twisy; Mahmoud Hr Hafez; Ibrahim M Sayed; Mohamed A El-Mokhtar
Journal:  Microorganisms       Date:  2022-05-31

2.  Virulence, Speciation and Antibiotic Susceptibility of Ocular Coagualase Negative Staphylococci (CoNS).

Authors:  Ravindran Priya; Arumugam Mythili; Yendremban Randhir Babu Singh; Haridas Sreekumar; Palanisamy Manikandan; Kanesan Panneerselvam; Coimbatore Subramanian Shobana
Journal:  J Clin Diagn Res       Date:  2014-05-15

3.  Analysis of some common pathogens and their drug resistance to antibiotics.

Authors:  Lidao Bao; Rui Peng; Xianhua Ren; Ruilian Ma; Junping Li; Yi Wang
Journal:  Pak J Med Sci       Date:  2013-01       Impact factor: 1.088

Review 4.  Biofilms in infections of the eye.

Authors:  Paulo J M Bispo; Wolfgang Haas; Michael S Gilmore
Journal:  Pathogens       Date:  2015-03-23

5.  Whole-Genome Sequences of Staphylococcus haemolyticus Isolated from Infected Eyes and Healthy Conjunctiva in Bhubaneswar, India.

Authors:  Sasmita Panda; Durg V Singh
Journal:  Genome Announc       Date:  2016-03-17

6.  The resident pathobiont Staphylococcus xylosus in Nfkbiz-deficient skin accelerates spontaneous skin inflammation.

Authors:  Yeji Kim; Yong-Soo Lee; Jin-Young Yang; Su-Hyun Lee; Yun-Yong Park; Mi-Na Kweon
Journal:  Sci Rep       Date:  2017-07-24       Impact factor: 4.379

7.  Identification of Novel Sequence Types among Staphylococcus haemolyticus Isolated from Variety of Infections in India.

Authors:  Sasmita Panda; Smrutiti Jena; Savitri Sharma; Benu Dhawan; Gopal Nath; Durg Vijai Singh
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

8.  Biofilm Formation by ica-Negative Ocular Isolates of Staphylococcus haemolyticus.

Authors:  Sasmita Panda; Durg Vijai Singh
Journal:  Front Microbiol       Date:  2018-11-14       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.